Cadeler Announces Signing of an EIFO-Backed Green Term Loan Facility of EUR 247 Million for Wind Apex

Cadeler Announces Signing of an EIFO-Backed Green Term Loan Facility of EUR 247 Million for Wind Apex

COPENHAGEN, Denmark–(BUSINESS WIRE)–Cadeler has signed an EIFO-backed senior secured green term loan facility of EUR 247 million to finance in part the construction of its third A-class newbuild offshore wind installation vessel, Wind Apex, with delivery expected in Q2 2027.

The 12-year facility is supported by the Export and Investment Fund of Denmark (EIFO) and has been designated as green financing under Cadeler’s Green Finance Framework.

The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch acted as Coordinator, Mandated Lead Arranger, Facility Agent, Security Agent and EIFO Agent. The lending syndicate comprises HSBC, KfW IPEX-Bank, Coöperatieve Rabobank U.A. and DNB Bank ASA.

Commenting on the financing, Mikkel Gleerup, CEO of Cadeler, says: “We are pleased to have secured this financing for Wind Apex together with a strong group of international banking partners. We greatly value our longstanding relationship with EIFO and appreciate their continued support for Cadeler’s growth. Their backing, together with that of our lending partners, reflects continued confidence in Cadeler and our ability to deliver the offshore wind installation capacity our customers need.”

Peter Boeskov, COO at EIFO Large Corporates comments: “Strengthening Danish companies and supply chains in the energy transition is a strategic priority for EIFO. Cadeler exemplifies how quickly Danish expertise can scale globally, now operating the world’s largest installation fleet for offshore wind. With this third transaction, we reaffirm our long-term commitment to supporting Cadeler’s continued growth.”

About Cadeler:

Cadeler A/S (Cadeler) is a pure-play offshore wind installation partner and a global leader in offshore wind turbine transport and installation. The company owns and operates the industry’s largest fleet of jack-up offshore wind installation vessels and is expanding its capabilities into full-scope foundation transport and installation, as well as operations & maintenance. With its modern fleet and depth of expertise across onshore and offshore operations, Cadeler supports the safe, efficient and reliable delivery of offshore wind projects worldwide. Cadeler is listed on the New York Stock Exchange (ticker: CDLR) and the Oslo Stock Exchange (ticker: CADLR). For more information, please visit www.cadeler.com.

For further information, please contact:


Mikkel Gleerup

CEO, Cadeler

+45 3246 3102

[email protected]

Alexander Simmonds

EVP & CLO, Cadeler

+44 7376 174172

[email protected]

KEYWORDS: Denmark Europe

INDUSTRY KEYWORDS: Building Systems Commercial Building & Real Estate Alternative Energy Construction & Property Energy Green Technology Sustainability Finance Professional Services Other Transport Environment Environmental Health Maritime Transport Other Construction & Property

MEDIA:

Logo
Logo

Webuy Launches AI Agent-Assisted Smart Travel Card to Enhance Connected Travel Experience

Singapore, July 13, 2026 (GLOBE NEWSWIRE) — Webuy Global Ltd (Nasdaq: WBUY) (“Webuy” or the “Company”), a technology-driven platform transforming travel services and social commerce across Southeast Asia, today announced the launch of its AI Agent-Assisted Smart Travel Card, a new travel technology initiative designed to support travelers across the full journey — from pre-departure preparation and payment to transportation, destination experiences and post-trip engagement.

The initiative applies AI Agent capabilities to selected travel workflows by combining AI-assisted decision-making, structured journey context, location-based detection, rules-based workflows and backend system integrations to provide more connected and context-aware travel services.

A customer journey can span weeks or months and involve numerous interactions, including preparation, transportation, itinerary management and destination services. Today, many of these interactions remain fragmented across messages, documents, applications and offline services.

Webuy’s Smart Travel Card is designed to bring these interactions together.

Combining an NFC-enabled physical card with a personalized H5 interface, the platform provides travelers with a continuous digital connection throughout the journey without requiring a separate application.

The current H5 interface provides access to journey information, meeting-point guidance, direct guide contact, daily itineraries, bilingual support and location-based AI attraction commentary.

As one example of its AI Agent-assisted functionality, the Smart Travel Card uses location and itinerary context to determine when a traveler is within approximately 300 meters of a relevant attraction. The system then automatically displays corresponding attraction information and AI-assisted audio commentary through the H5 interface, allowing the traveler to choose whether to play the audio content.By connecting more of the customer journey through a single platform, Webuy believes it may be able to build a more continuous understanding of how travelers interact with its products and services.

Webuy believes this may support a long-term improvement cycle for the travel business: as more customers use the platform, the Company may gain deeper insights into traveler needs; those insights may help improve its AI Agents and products; and better experiences may support stronger engagement, referrals and repeat business.

“Our Smart Travel Card is designed to help understand where the traveler is in the journey and support timely, relevant services from Webuy. For example, when a traveler enters the proximity of a relevant attraction, the system can evaluate the traveler’s location and journey context and automatically provide corresponding attraction information and AI-assisted commentary. We believe this can improve the travel experience by supporting a more connected and personalized journey from beginning to end. Just as importantly, it may help strengthen the data and service feedback loop within our travel business. As our customer base grows, the insights generated through these interactions may help us improve our AI Agents, products and services, supporting stronger engagement, referrals and repeat business over time,” said Vincent Xue, Chief Executive Officer of Webuy Global Ltd.

The initiative forms part of Webuy’s broader strategy to deploy AI Agents across its travel operations and build a more connected and scalable technology-driven travel business.

About WEBUY GLOBAL LTD (Nasdaq: WBUY)

Webuy is a technology-driven platform transforming travel services and social commerce across Southeast Asia.The Company provides curated leisure travel experiences, cross-border tour services, premium travel offerings, customized travel solutions, and region-wide travel services for customers in Indonesia, Singapore, and international markets. Webuy is focused on building an integrated travel ecosystem powered by AI, service excellence, and strong regional partnerships. For more information, visit www.webuy.global.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results, and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the U.S. Securities and Exchange Commission (the “Commission”) before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequently occurring events or circumstances, or changes in its expectations, except as may be required by law.

Attachments



Investor & Media Contact
WEBUY GLOBAL LTD
Email: [email protected]

Niu Technologies to Report Second Quarter 2026 Financial Results on August 10, 2026

BEIJING, July 13, 2026 (GLOBE NEWSWIRE) — Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced that it will report its financial results for the second quarter 2026 before the U.S. market opens on Monday, August 10, 2026.

The corporate presentation and financial spreadsheets will be posted on NIU’s investor relations website at:
https://ir.niu.com/financial-information/quarterly-results

The Company will host an earnings conference call on Monday, August 10, 2026 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time) to discuss the financial and business results.

To join via phone, participants need to register in advance of the conference call using the link provided below. Upon registration, participants will receive dial-in numbers and a personal PIN, which will be used to join the conference call.

Event: Niu Technologies Second Quarter 2026 Financial Results Conference Call
Registration Link: https://register-conf.media-server.com/register/BI86bdc4efa3794d128f27c2a1d70cc7df


A live and archived webcast of the conference call will be available on the investor relations website at https://ir.niu.com/news-and-events/webcasts-and-presentations

About NIU

As the world’s leading provider of smart urban mobility solutions, NIU designs, manufactures and sells high-performance electric motorcycles, mopeds, bicycles, as well as kick-scooters and e-bikes. NIU has a diversified product portfolio that caters to the various demands of our users and addresses different urban travel scenarios. Currently, NIU offers two model lineups, comprising a number of different vehicle types. These include (i) the electric motorcycle, moped and bicycle series, including the NQi, MQi, UQi, FQi series and others, and (ii) the micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. NIU has adopted an omnichannel retail model, integrating the offline and online channels, to sell its products and provide services to users.

For more information, please visit www.niu.com.

Investor Relations Contact:

Niu Technologies
E-mail: [email protected]
             



Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD)

Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over multiple doses in this study

Pivotal Phase 3 VIVID-6 trial evaluating latarcibart’s potential to be the first targeted therapy for VWD is currently enrolling

WILMINGTON, Del.–(BUSINESS WIRE)–
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris.

Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Given its novel mechanism, latarcibart may also have potential in other bleeding disorders.

“These results continue to build a highly consistent body of evidence supporting latarcibart as a significant potential treatment advancement for patients with VWD,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “This multidose dataset underscores the potential of latarcibart to address the longstanding need for a prophylactic therapy that provides meaningful protection for patients with all types of VWD. We are continuing to enroll the Phase 3 VIVID-6 study as we work toward redefining the standard of routine prophylactic care for patients with VWD.”

As of May 5, 2026, data from all 16 patients enrolled in the Phase 1/2 multidose study were available, and all participants had completed the multidose regimen of six doses of latarcibart, with maintenance doses administered subcutaneously every four weeks. Key data highlights include:

  • Substantial reductions in ABR (annualized bleeding rate) were seen across study patients, including all VWD types and bleed types, such as serious GI and hemophilia-like joint and muscle bleeds.

    • The median ABR reduction across all VWD types and bleed categories was 81%.

    • In patients switching from prior von Willebrand factor (VWF)-containing prophylaxis (IV infusions multiple times per week), bleed reductions were 75-100%, indicating potential improvement over current standard of care.

    • Among patients not previously receiving IV prophylaxis, 7 had historical ABRs >12, a key eligibility criterion for the Phase 3 VIVID-6 study. In this group, ABR reductions ranged from 46-100%, with nearly all patients (6/7) achieving reductions >73%.

    • Latarcibart treatment resulted in ~86% reduction in VWF-treated breakthrough bleeds, with 70% of patients with prior VWF-treated bleeds not experiencing a VWF-treated breakthrough bleed while on treatment.

  • All participants who entered the study with a substantial bleed burden transitioned to continue receiving latarcibart in the ongoing open-label extension study.

  • Latarcibart once monthly subcutaneous prophylaxis was safe and well tolerated over multiple doses.

    • Three treatment-emergent adverse events (TEAEs) related to latarcibart were reported: two Grade 2 headaches in one patient and one report of Grade 1 injection site reactions. There was also one unrelated serious adverse event of severe gastrointestinal (GI) bleeding in a patient with a history of frequent and severe GI bleeding.

“Many people with VWD struggle with bleeding and need more effective and convenient prophylactic treatments. The study results showed treatment with latarcibart delivered consistent and clinically meaningful reductions in bleeding across a diverse group of VWD patients, including patients with all major types of the disease and individuals transitioning from intensive IV prophylaxis,” said Allison Wheeler, M.D., MSCI, Associate Professor of Pediatrics at the University of Washington. “Equally important, the favorable safety profile and once monthly subcutaneous dosing regimen have the potential to substantially reduce treatment burden while providing consistent bleed protection. Together, these findings provide a strong foundation for the Phase 3 study and support latarcibart’s potential as an important new treatment option for patients with VWD.”

More information regarding the ISTH 2026 Congress can be found on the ISTH website: https://www.isthcongress.org/ (Session details: Novel Therapies for Bleeding Disorders, Including VWD and Rare Bleeding Disorders – 2; Publication Number: OC 32.3).

About VGA039 (latarcibart)

VGA039 (latarcibart) is an investigational monoclonal antibody therapy with a novel mechanism of action that targets Protein S, with dual actions promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. Latarcibart has the potential to be a universal prophylactic therapy for numerous bleeding disorders, starting with all types of von Willebrand disease (VWD) and bleeding sites. As a subcutaneously self-administered investigational antibody therapy with a once monthly dosing regimen, latarcibart has the potential to improve bleeding outcomes, convenience, and quality of life for patients.

Latarcibart has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration (FDA). Latarcibart has advanced into the Phase 3 VIVID-6 study (NCT07115004), a global single arm cross-over study to investigate safety and efficacy of the subcutaneous administration of latarcibart as prophylaxis for bleeding in patients with every type of VWD, including those with a high disease burden.

Incyte acquired VGA039 (latarcibart) in July 2026 as part of its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC.

About the VIVID Clinical Program

The VIVID multinational clinical program consists of multiple clinical trials, from Phase 1 to 3, in both a platform multi-phase protocol (VIVID-1-5) and a standalone Phase 3 protocol (VIVID-6) evaluating the safety and efficacy of VGA039 in VWD. The VIVID clinical program is active across 6 continents and designed to support future registrational filings globally.

About von Willebrand Disease

Von Willebrand disease (VWD) is the most common inherited bleeding disorder in which the blood does not clot properly, caused by low or defective von Willebrand factor (VWF). People with VWD may experience excessive bleeding with varying severity and frequency, negatively impacting their daily lives. Current therapies for VWD prophylaxis include factor replacement therapies requiring multiple intravenous (IV) infusions every week. Approximately 135,000 people in the United States have been diagnosed with von Willebrand disease.1

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the data to be presented by Incyte at the ISTH 2026 Congress; Incyte’s expectations regarding VGA039’s (latarcibart’s) clinical development and regulatory approvals; the potential and promise latarcibart offers patients with bleeding disorders, including the potential to be the first once monthly subcutaneous prophylactic therapy for patients with VWD, its potential improvement over current standards of care for patients with VWD and other bleeding disorders, and its potential ability to address significant unmet need, reduce treatment burden and improve quality of life; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including results from clinical trials of and the sufficiency of clinical trial data for latarcibart, as well as Incyte’s other products and product candidates, to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Incyte’s ability to achieve commercial success for latarcibart, if approved; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.

1

Data on File.

 

Media

[email protected]

Investors

[email protected]

KEYWORDS: Delaware Europe United States North America France

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo
Logo

Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™

Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™

Combined market up 46%, led by 64% growth in cloud services

Managed services up 21%, as companies seek cost savings to fund AI

LONDON–(BUSINESS WIRE)–
Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.

The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent.

“Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital transformation,” said Anthony Drake, president, ISG EMEA. “We’re seeing strong double-digit growth pretty much across the board.”

Second-Quarter Results by Segment

ACV for the as-a-service (XaaS) segment surged 64 percent year on year, its fastest growth ever, to a record US $8.3 billion, as demand for hyperscaler services to support AI skyrocketed. It was the ninth straight quarter XaaS has grown by double digits, averaging 38.5 percent growth in that span.

Within this segment, infrastructure-as-a-service (IaaS) climbed 79 percent year on year, to a record US $6.8 billion. Software-as-a-service (SaaS) grew 19 percent versus the prior year, to US $1.5 billion.

Managed services ACV in the second quarter advanced 21 percent, to US $4.7 billion. A total of 294 managed services contracts were awarded in the quarter, up 23 percent from the prior year. Among them were two mega deals (ACV of US $100 million or more), compared with three signed in the second quarter last year, as mega-deal ACV dropped 56 percent year on year. At the other end of the spectrum, the number of smaller awards (those in the US $5 million to US $9 million range) rose 11 percent from the prior year.

Managed services growth in Q2 was driven by new scope activity, with the number of deals up 25 percent and the ACV of those deals up 32 percent, to US $3.3 billion, as enterprises continued to consolidate their provider ecosystems and turn to smaller, niche providers for specialized services.

Within managed services, IT outsourcing (ITO) rose 21 percent, to US $3.2 billion, led by growth in application development and maintenance (ADM) and infrastructure services. Business process outsourcing (BPO) grew 37 percent, to US $915 million, led by growth in industry-specific and facilities management services. Engineering, research and development (ER&D) services advanced 3 percent year on year, to US $519 million, and was up 30 percent from a slow first quarter.

By industry, managed services ACV was sharply higher (up 55 percent) in banking, financial services and insurance (BFSI), as well as in travel, transportation and leisure (up 51 percent), and energy (up 34 percent), which extended its growth trajectory to four straight quarters. For BFSI, it was the first time in nine quarters that the sector’s spending trended higher. Manufacturing, meanwhile, was down 7 percent, its third straight quarter of negative results.

Geographic Performance

EMEA’s largest managed services market, the U.K., posted its best quarter in the last three years, with ACV of US $1.4 billion, up 84 percent year on year. The region’s other traditional powerhouses, DACH and France, however, moved to the downside. DACH declined 5.5 percent, to US $917 million, while France slid 59 percent, to US $332 million. Eastern Europe and Southern Europe each advanced by triple-digits, while the Nordics was up 1.4 percent.

First-Half Results

For the first half, combined market ACV rose 37 percent, to US $25.0 billion. Managed services, at US $9.3 billion, was up 13 percent, while XaaS, at US $15.7 billion, climbed 56.5 percent. A total of 578 managed services contracts were awarded in the half, up 12 percent from last year, including five mega-deals, one fewer than the prior year, as the ACV of those deals fell 29 percent.

Within managed services, ITO was essentially flat (down 0.2 percent), at US $6.2 billion, while BPO surged 86 percent, to US $2.3 billion. On the cloud side, the IaaS market rocketed by 74 percent, to US $12.8 billion, while the SaaS market rose a more modest 8 percent, to US $2.9 billion.

2026 Global Forecast

For the full year, ISG said it is maintaining its global forecast of 2.1 percent revenue growth for managed services. At the same time, ISG is raising its previous growth forecast for cloud-based XaaS by 500 basis points, to 30 percent, reflecting continuing strong demand for AI infrastructure and software services.

About the ISG Index™

The ISG Index™ is recognized as the authoritative source for marketplace intelligence on the global technology and business services industry. For 95 consecutive quarters, it has detailed the latest industry data and trends for financial analysts, enterprise buyers, software and service providers, law firms, universities and the media.

The 2Q26 Global ISG Index results were presented during a webcast on July 9. To view a replay of the webcast and download presentation slides, visit this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Philipp Jaensch, ISG

+49 151 730 365 76

[email protected]

Will Thoretz, ISG

+1 203 517 3119

[email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Consulting Data Management Technology Professional Services Security Data Analytics Software Artificial Intelligence Networks Internet Hardware

MEDIA:

Logo
Logo

WeRide Accelerates Global Expansion of Its End-to-End Intelligent Driving Solution

Key Highlights

  • WeRide’s one-stage end-to-end intelligent driving solution, built on its proprietary end-to-end driving algorithm and co-developed with Bosch, has begun on-road testing and localization validation in Germany, France, Japan and other international markets.
  • WeRide is building a global integrated engineering and validation framework spanning R&D, testing, adaptation across diverse international markets.
  • The solution’s unified end-to-end AI architecture enables rapid adaptation across diverse traffic regulations, road environments, driving cultures and climate conditions.

GUANGZHOU, China, July 13, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, today disclosed progress in the international expansion of its L2++ intelligent driving business. Built on WeRide’s proprietary one-stage end-to-end intelligent driving algorithm and integrated with Bosch’s automotive-grade domain controller platform and global validation expertise, the one-stage end-to-end intelligent driving solution has begun on-road testing and localization validation in Germany, France, Japan and other international markets. Through these efforts, WeRide continues to accumulate experience across diverse driving scenarios while systematically strengthening its product development and engineering validation capabilities for global markets.


A test vehicle on the road in Germany

As intelligent driving becomes a critical competitive differentiator for automakers expanding beyond their home markets, the industry’s focus is shifting from single-market optimization to global capability building. Delivering a consistent, safe and comfortable driving experience across different regulatory frameworks, road infrastructures, driving behaviors and environmental conditions is emerging as one of the defining challenges for next-generation intelligent driving systems.


A test vehicle on the road in Japan

To address this challenge, WeRide is systematically expanding its global engineering and validation capabilities. Together with Bosch, one of the world’s leading automotive suppliers, the company is conducting on-road testing and adaptation programs in key international markets, including Germany, France and Japan. These efforts are helping WeRide accumulate experience across diverse driving environments while building a full-cycle engineering framework covering R&D, testing, validation and commercial deployment.

At the same time, WeRide is working closely with multiple automakers to better understand local mobility needs, driving behaviors and customer preferences. By incorporating regional road characteristics, regulatory requirements and driving cultures into product development, the company continues to refine the features and capabilities that deliver the greatest value to users worldwide.


Dr. Tony Han, Founder and CEO of WeRide (Left)
Mr. Wu Yongqiao, Regional President of Bosch Cross-Domain Computing Solutions China (Right)
at IAA Mobility 2025 in Munich

The solution is powered by a unified end-to-end AI architecture that integrates perception, prediction, planning and control within a single model while supporting both driving and parking scenarios. It brings together WeRide’s latest advancements in end-to-end AI models, system-level integration and hardware-software co-optimization.

The architecture enables more efficient understanding of complex interactions among vehicles, pedestrians and surrounding infrastructure while reducing cumulative system errors. As a result, the solution delivers stronger scene understanding, broader scenario generalization and enhanced safety redundancy, allowing it to adapt rapidly to diverse driving environments around the world.

From Germany’s unrestricted autobahns and France’s dense roundabouts to right-hand-drive markets in Japan and Southeast Asia, as well as the extreme climate conditions of the Middle East, the solution is designed to support scalable deployment across a wide range of global operating environments.

While expanding its international validation footprint, WeRide’s one-stage end-to-end intelligent driving solution continues to demonstrate strong performance in China’s highly complex traffic conditions. Over the past six months, Chery Exeed ES and ET models equipped with WRD 3.0 have secured six consecutive victories in the China Intelligent Driving Challenge. The solution has also achieved design wins across more than 30 production vehicle programs with leading automakers, including Chery and GAC Group, demonstrating growing commercial adoption alongside its technology leadership.

As global demand for intelligent driving technologies continues to grow, WeRide is leveraging experience gained from China’s complex road environments together with ongoing overseas validation efforts to strengthen the adaptability and robustness of its end-to-end intelligent driving solution. By extending testing and adaptation across diverse markets, the company is bringing proven capabilities from China to driving environments around the world.

About WeRide
WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been tested or operated in over 40 cities across 12 countries. We are also the first and only technology company whose products have received autonomous driving permits in eight markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune’s 2025 Change the World and 2025 Future 50 lists.

Media Contacts
WeRide: [email protected]

Safe Harbor Statement
This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/ac1396fa-11ac-4fdd-9f9d-c3cb8f3456fa
https://www.globenewswire.com/NewsRoom/AttachmentNg/8fc2c709-528d-4e4c-863f-7bcd351528b1
https://www.globenewswire.com/NewsRoom/AttachmentNg/34cbb9ee-2a28-4edf-8515-4c59ce39b850
https://www.globenewswire.com/NewsRoom/AttachmentNg/3849bf22-9e81-4c34-8235-ec5ecfde2b77



Marti and Tensor Partner to Deploy Autonomous Vehicles in Türkiye

Marti and Tensor Partner to Deploy Autonomous Vehicles in Türkiye

ISTANBUL–(BUSINESS WIRE)–
Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye’s leading mobility super app, and Tensor, a pioneer in personal autonomous vehicles, today announced a multi-year strategic partnership to purchase and deploy Tensor autonomous vehicles (“AVs”) on Marti’s mobility platform in cities across Türkiye.

Marti currently offers ride-hailing services in 20 cities across Türkiye representing approximately 80% of the country’s GDP, including Istanbul, Ankara, Izmir, Kocaeli, Bursa, Antalya, Konya, Adana, Mersin, Gaziantep, Tekirdağ, Manisa, Kayseri, Muğla, Sakarya, Samsun, Eskişehir, Denizli, Aydın, and Yalova. Following launch, Marti platform consumers will be able to hail Tensor autonomous vehicles directly within the Marti app.

Founded in Silicon Valley in 2016, Tensor is the first company to develop a Level 4 autonomous vehicle designed from the ground up for both personal ownership and professional fleet operations. Leveraging a decade of AV development and holding California’s second-ever driverless testing permit for passenger vehicles, Tensor revealed the world’s first personal Robocar in August 2025. While purpose-built for private owners, the platform is fully functional for fleet deployment, featuring native ride-share capabilities that allow the vehicle to be seamlessly integrated into global autonomous mobility networks. To maximize fleet uptime and performance, Tensor’s architecture features a vertically integrated compute and sensor stack alongside proprietary sensor cleaning technology, enabling rapid scaling of operational design domains and seamless enhancements via deep over-the-air (“OTA”) updates that extend down to the firmware level.

The Tensor Robocar is powered by its proprietary supercomputer which includes 8x Thor-X NVIDIA GPU’s, which supports its sophisticated onboard AI and a safety-first architecture utilizing high-redundancy systems.

“Our strategic collaboration with Marti is a bold step in our mission to democratize autonomy and bring a premium autonomous experience to Marti platform consumers,” said Dr. Jay Xiao, CEO of Tensor. “Building on our recent partnership announcements in the USA, UAE, and Europe, this partnership reaffirms our global commitment to bringing the luxury of safe, efficient, and scalable autonomous mobility to the world. Together with Marti, we are excited to deliver the cutting edge of transportation technology to platform consumers across Türkiye.”

“As Türkiye’s leading urban mobility platform, Marti has consistently pioneered the introduction of new tech-enabled transportation services across the country. We are proud to build on this track record by working to introduce autonomous ride-hailing to Türkiye in partnership with Tensor,” commented Oguz Alper Oktem, Founder and Chief Executive Officer of Marti. “With our extensive field operations team, established infrastructure, and approximately 7.8 million all-time unique platform consumers, Marti is well positioned to support the rapid, safe deployment of Tensor’s autonomous vehicle fleet in the years ahead.”

About Tensor

Tensor is an American AI company dedicated to building agentic products that empower people. Its flagship product, the Tensor Robocar, is the world’s first personal Robocar and the first AI agentic vehicle—fully autonomous, automotive-grade, and engineered for private ownership at scale. Founded in 2016 in Silicon Valley and headquartered in San Jose, California, Tensor maintains a global footprint with offices in Barcelona, Singapore, and Dubai.

Since its inception, Tensor has consistently led the autonomous mobility landscape. The company secured its first California public road testing permit in 2017 and subsequently achieved two historic regulatory milestones: becoming the second company in California history to receive a CPUC permit for public RoboTaxi testing (2019) and the second to obtain a DMV permit for fully driverless passenger vehicle operation (2020). Today, Tensor continues to pioneer the future of Agentic AI by delivering Level 4 autonomous technology to both global ride-hailing networks and private owners.

About Marti

Founded in 2018, Marti is Türkiye’s leading mobility app, offering a wide variety of transportation services. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers; offers delivery services; and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti’s offerings are serviced by proprietary software systems and IoT infrastructure. For more information, visit www.marti.tech.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact and generally relate to future events, hopes, intentions, strategies, or performance may be deemed to be forward-looking statements, including, without limitation, statements regarding the anticipated benefits, scope, timing, and impact of Marti’s strategic partnership with Tensor, the expected deployment, performance, safety, and regulatory approval of autonomous vehicles in Türkiye, the potential market adoption of autonomous ride-hailing services, and the Company’s expectations with respect to its operations, expansion plans, technology development, and future growth. These forward-looking statements are based on management’s current expectations and beliefs as of the date they are made. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risks discussed in the Company’s filings with the SEC, including the Company’s Annual Report on Form 20-F. The Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of future events, new information or otherwise, except as required by law.

Investor Contact

Marti Technologies, Inc.

Turgut Yilmaz

[email protected]

Tensor Media Relations

[email protected]

KEYWORDS: Europe United States Turkey North America California

INDUSTRY KEYWORDS: Hardware IOT (Internet of Things) Retail Technology Robotics Transportation Apps/Applications Travel Autonomous Driving/Vehicles Artificial Intelligence Fleet Management Delivery Services Automotive Software Internet Mobile/Wireless

MEDIA:

Logo
Logo

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer’s Disease and Related Dementias (ADRD) participants using Alamar Biosciences’ NULISAseq™ Neuro 220 panel. | Resulting dataset will be publicly accessible, linked through National Alzheimer’s Coordinating Center IDs and open to AI-driven discovery through a national data challenge. | Project is part of the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) portfolio, leveraging academic, philanthropic, and data-sharing partnerships for large-scale biomarker discovery.

Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced a partnership with leading research universities to launch a national-scale proteomics initiative using Alamar Biosciences’ NULISAseq Neuro 220 panel to accelerate biomarker discovery and validation for Alzheimer’s disease and related neurodegenerative conditions.

The project is co-led by professors Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin; and Tatiana Foroud, PhD, director of the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) at Indiana University. The project will generate large-scale plasma proteomic data from approximately 21,000 samples collected from 10,000 Alzheimer’s Disease Research Center (ADRC) participants across the United States. Samples are stored at NCRAD, providing a centralized national infrastructure for coordinated access and biomarker generation at scale.

Profiling will use Alamar Biosciences’ NULISAseq™ Neuro 220 panel, enhanced with a newly added eMTBR-Tau assay that enables simultaneous blood-based representation of tau tangle burden alongside a broad panel of neurodegeneration and neuroinflammation biomarkers. The panel also offers the largest number of brain-derived Tau targets along with assays relevant to alpha-synuclein biology and other protein aggregation markers, creating a unique opportunity to study multiple neurodegenerative disease pathways in the same deeply characterized participants.

“Our precision proteomics platform is designed to give researchers the ability to measure hundreds of low-abundance proteins from blood with attomolar sensitivity, at scale, and across highly multiplexed panels,” said Dr. Yuling Luo, founder, chief executive officer and chair of Alamar. “Applying that capability to a cohort of this size will give researchers access to a deeply multiplexed, clinically anchored proteomic dataset that can support discovery, validation, and translational research across a range of neurodegenerative diseases. We see this as a major step toward understanding the full biological complexity of neurodegenerative disease.”

The project is part of the CLARiTI portfolio and leverages its infrastructure to support coordinated sample access and harmonized data workflows. The effort has been advanced through sustained partnerships with the Alzheimer’s Association, the Robertson Foundation, an anonymous foundation, and important implementation and data-sharing support from the Alzheimer’s Disease Data Initiative. All data generated through the initiative will be made freely available to the global research community.

A central goal is the creation of an open, publicly accessible proteomic dataset linked to National Alzheimer’s Coordinating Center (NACC) IDs. This linkage will allow researchers to connect the new proteomic profiles with rich longitudinal data available through the ADRC Program, including clinical, cognitive, neuroimaging, genetic, genomic, fluid biomarker, and neuropathology data. AI and computational teams will apply multimodal approaches for disease classification, biomarker discovery, and prediction of neurodegenerative disease progression. The next phase of the project will include a national data challenge inviting the broader research community to develop and test new analytical methods using this resource.

 “This effort is designed to move the field from single-disease models toward a more comprehensive understanding of the biological processes that contribute to mild cognitive impairment and dementia,” said Dr. Sterling Johnson. “Because ADRCs across the United States enroll and study diverse research participants, this multi-site cohort aligns well with the study’s scientific objectives. By generating an open, national-scale resource and engaging leading AI and computational teams, we also hope to accelerate discovery and create tools that ultimately improve diagnosis, treatment development, and patient care.”

About Alamar Biosciences

Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range, and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com

Forward Looking Statements

This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ ability to unlock high-quality multiplexed proteomic data from remotely collected samples, the capabilities and performance of the NULISAseq™ Neuro 220 panel and the eMTBR-Tau assay, and the expected size, scope, and scientific output of the proteomics initiative. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the SEC, including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.



Media Relations
Alamar Biosciences, Inc.
[email protected]

Investor Relations
Alamar Biosciences, Inc.
[email protected]

Stellantis Reports Q2 2026 Estimated Consolidated Shipments of 1.6 Million Units, +10% Year-Over-Year

Stellantis Reports Q2 2026 Estimated Consolidated Shipments of 1.6 Million Units, +10% Year-Over-Year

  • North America Shipments Up 38%, Driven by New Product Launches; Enlarged Europe Also Reports Growth

AMSTERDAM, July 13, 2026 – Stellantis N.V. today released its Q2 2026 estimated consolidated shipments. The term “shipments” describes the volume of vehicles delivered to dealers, distributors, or directly from the Company to retail and fleet customers, which generally drive revenue recognition.

Consolidated shipments for the three months ended June 30, 2026, were an estimated 1.6 million units, up 10% year-over-year. Growth was driven primarily by North America and Enlarged Europe, partially offset by lower volumes in the Middle East & Africa, largely due to the regional conflict, and in South America, where a weaker Argentine market weighed on performance.

  • In North America, Q2 shipments increased by approximately 122 thousand units, or 38% year-over-year. The majority of the growth was driven by new or refreshed products and powertrain offerings, including the Ram 1500 (light-duty) HEMI® V8, the new Ram 1500 TRX SRT, the refreshed Jeep® Grand Wagoneer and Grand Cherokee, and the refreshed Chrysler Pacifica, in addition to the continued ramp-up of the all-new Jeep® Cherokee and the all-new Dodge Charger 2-door and 4-door SIXPACK; it also reflects preparations for the planned summer production shutdown.
  • In Enlarged Europe, Q2 shipments increased by approximately 39 thousand units, or 5% year-over-year, supported by higher industry volumes. Growth came from both Stellantis- and Leapmotor-branded vehicles, with BEV shipments serving as the primary driver. For Stellantis brands, shipment growth was driven primarily by recent product launches. Strong demand for Smart Car platform nameplates including the Citroën C3 and C3 Aircross, Opel/Vauxhall Frontera, and Fiat Grande Panda, contributed approximately 41 thousand additional units, representing 51% growth year-over-year. In the C-segment, the new Jeep® Compass also contributed positively, adding approximately 8 thousand units. These gains were partially offset by an approximately 28-thousand unit decline in shipments of legacy B-SUV models, including Jeep Avenger, Fiat 600, Opel Mokka and Peugeot 2008. Leapmotor-branded vehicle shipments increased by approximately 25 thousand units to 33 thousand units, driven by strong demand for the T03 and the B10.
  • In Middle East & Africa, shipments declined by approximately 4 thousand units, or 3% year-over-year, reflecting the impact of the regional conflict. Growth in the region was supported by Algeria, up approximately 8 thousand units, from the continued ramp-up of the Fiat Doblo and, to a lesser extent, higher shipments in Morocco driven by stronger industry volumes. These gains were more than offset by Türkiye, down approximately 8 thousand units, amid weaker market conditions, and shipments in Gulf Cooperation Council countries, which declined by approximately 50%.
  • In South America, shipments declined by approximately 7 thousand units, or 3% year-over-year. The growth in Brazil, up approximately 21 thousand units, supported by favorable industry conditions, was more than offset by lower shipments in other markets, mainly in Argentina, where shipments declined by approximately 25 thousand units.
  • Asia Pacific shipments remained flat year-over-year at 16 thousand units.

NOTES

(1)  Consolidated shipments only include shipments by the Company’s consolidated subsidiaries, which represent new vehicles invoiced to third parties (dealers/importers or final customers). Consolidated shipment volumes for Q2 2026 presented here are unaudited and may be adjusted.

With effect from January 1, 2026, our Maserati reportable segment has been eliminated, and its shipments are reported consistently with our other brands, in that transactions are treated on a “where sold” basis. Comparative information has been restated.

Consolidated shipments include shipments for Leapmotor International, which is a jointly established, Stellantis-controlled company created in 2024 and owned 51 percent by Stellantis and 49 percent by Leapmotor, to distribute Leapmotor-branded vehicles outside of China.

# # #


About Stellantis

Stellantis (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep

®

, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information,

www.stellantis.com

@Stellantis Stellantis Stellantis Stellantis
 

For more information, contact:

   [email protected]

Fernão SILVEIRA +31 6 43 25 43 41 – [email protected]

[email protected]
www.stellantis.com

 


Safe Harbor Statement

This document, in particular references to “FY 2026 Financial Guidance”, contains forward looking

statements. In particular, statements regarding future financial performance and the Company’s

expectations as to the achievement of certain targeted metrics, including revenues, industrial free cash flows, vehicle shipments, capital investments, research and development costs and other expenses at any future date or for any future period are forward looking statements. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, or similar terms. Forward looking statements are not guarantees of future performance. Rather, they are based on the Company’s current state of knowledge, future expectations and projections about future events and are by their nature, subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them.

Actual results may differ materially from those expressed in forward looking statements as a result of a variety of factors, including: the Company’s ability to maintain vehicle shipment volumes; changes in the global financial markets, general economic environment and changes in demand for automotive products, which is subject to cyclicality; changes in trade policy, the imposition of global and regional tariffs targeted to the automotive industry; the Company’s ability to accurately predict the market demand for electrified vehicles; the Company’s ability to offer innovative, attractive products; a significant malfunction, disruption or security breach compromising information technology systems or the electronic control systems contained in the Company’s vehicles; the Company’s ability to attract and retain experienced management and employees; exchange rate fluctuations, interest rate changes, credit risk and other market risks; increases in costs, disruptions of supply or shortages of raw materials, parts, components and systems used in the Company’s vehicles; changes in local economic and political conditions; the enactment of tax reforms or other changes in tax laws and regulations; the level of governmental economic incentives available to support the adoption of battery electric vehicles; the impact of increasingly stringent regulations regarding fuel efficiency and greenhouse gas and tailpipe emissions; various types of claims, lawsuits, governmental investigations and other contingencies, including product liability and warranty claims and environmental claims, investigations and lawsuits; material operating expenditures in relation to compliance with environmental, health and safety regulations; the level of competition in the automotive industry, which may increase due to consolidation and new entrants; exposure to shortfalls in the funding of the Company’s defined benefit pension plans; the Company’s ability to provide or arrange for access to adequate financing for dealers and retail customers; risks related to the operations of financial services companies; the Company’s ability to access funding to execute its business plan; the Company’s ability to realize anticipated benefits from joint venture arrangements; disruptions arising from political, social and economic instability; risks associated with the Company’s relationships with employees, dealers and suppliers; the Company’s ability to maintain effective internal controls over financial reporting; developments in labor and industrial relations and developments in applicable labor laws; earthquakes or other disasters; and other risks and uncertainties.

Any forward-looking statements contained in this document speak only as of the date of this

document and the Company disclaims any obligation to update or revise publicly forward looking

statements. Further information concerning the Company and its businesses, including factors that

could materially affect the Company’s financial results, is included in the Company’s reports and filings with the U.S. Securities and Exchange Commission and AFM.

Attachment



First Hawaiian to Report Second Quarter 2026 Financial Results on July 24, 2026

HONOLULU, July 12, 2026 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its second quarter 2026 financial results on Friday, July 24, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time).

To access the call by phone, participants will need to click on the following registration link: https://register-conf.media-server.com/register/BIb8e318d9b8d24417b3d7d113fcf80dbc, register for the conference call, and then you will receive the dial-in number and a personalized PIN code. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the conference call, including a slide presentation, will be available at the following link: www.fhb.com/earnings. The archive of the webcast will be available at the same location.

About First Hawaiian

First Hawaiian, Inc. (NASDAQ:FHB) is a bank holding company headquartered in Honolulu, Hawaii. Its principal subsidiary, First Hawaiian Bank, founded in 1858 under the name Bishop & Company, is Hawaii’s oldest and largest financial institution with branch locations throughout Hawaii, Guam and Saipan. The company offers a comprehensive suite of banking services to consumer and commercial customers including deposit products, loans, wealth management, insurance, trust, retirement planning, credit card and merchant processing services. Customers may also access their accounts through ATMs, online and mobile banking channels. For more information about First Hawaiian, Inc., visit www.fhb.com.

Investor Relations Contact:
Kevin Haseyama
(808) 525-6268
[email protected]

Media Contact:

Bill Weeshoff
(808) 525-6229
[email protected]